Raymond James Financial Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price target decreased by equities researchers at Raymond James Financial from $355.00 to $263.00 in a note issued to investors on Thursday,MarketScreener reports. Raymond James Financial’s price objective points to a potential upside of 70.60% from the stock’s current price.

Several other research firms also recently issued reports on PODD. Canaccord Genuity Group reduced their price target on Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research note on Thursday. Robert W. Baird reduced their price target on Insulet from $360.00 to $248.00 in a research note on Thursday. BTIG Research dropped their price objective on Insulet from $320.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday. Leerink Partners dropped their price objective on Insulet from $360.00 to $247.00 in a report on Thursday. Finally, The Goldman Sachs Group lowered their price objective on shares of Insulet from $326.00 to $277.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Eighteen research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average target price of $257.09.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $154.16 on Thursday. The company has a current ratio of 2.49, a quick ratio of 2.15 and a debt-to-equity ratio of 0.71. Insulet has a 12 month low of $148.30 and a 12 month high of $354.88. The stock has a 50 day moving average of $211.22 and a 200-day moving average of $263.85. The company has a market capitalization of $10.68 billion, a P/E ratio of 35.85, a P/E/G ratio of 0.92 and a beta of 1.20.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts predict that Insulet will post 6.46 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction dated Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of institutional investors have recently modified their holdings of PODD. Norges Bank acquired a new position in shares of Insulet during the 4th quarter worth $300,794,000. RTW Investments LP acquired a new position in shares of Insulet during the 4th quarter worth $92,264,000. AQR Capital Management LLC increased its holdings in Insulet by 161.6% in the 4th quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock worth $130,499,000 after purchasing an additional 283,643 shares in the last quarter. SG Americas Securities LLC increased its holdings in Insulet by 712.1% in the 1st quarter. SG Americas Securities LLC now owns 318,848 shares of the medical instruments supplier’s stock worth $66,907,000 after purchasing an additional 279,587 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new position in Insulet in the 2nd quarter worth about $80,082,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.